Appendix Table A7.
Lung cancer treatments |
Average per-claim payment ($) |
Before integration | After integration |
---|---|---|---|
Nab-paclitaxel | $1,704 | 0.90% | 4.26% |
Gemcitabine | $385 | 8.78% | 14.45% |
Docetaxel | $119 | 9.01% | 12.90% |
Carboplatin | $26 | 59.68% | 43.10% |
Etoposide | $14 | 15.32% | 10.45% |
Paclitaxel | $32 | 26.58% | 21.29% |
Notes:
The distribution of the drugs among lung cancer patients.